Moleculin Biotech, INC. 8-K Filing
Ticker: MBRX · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1659617
Sentiment: neutral
Filing Stats: 622 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-11-21 16:33:36
Key Financial Figures
- $2.5 million — that the Company maintain a minimum of $2.5 million in stockholders' equity, and that the C
Filing Documents
- mbrx20251121_8k.htm (8-K) — 21KB
- logobig.jpg (GRAPHIC) — 19KB
- 0001437749-25-036006.txt ( ) — 203KB
- mbrx-20251120.xsd (EX-101.SCH) — 3KB
- mbrx-20251120_def.xml (EX-101.DEF) — 12KB
- mbrx-20251120_lab.xml (EX-101.LAB) — 15KB
- mbrx-20251120_pre.xml (EX-101.PRE) — 12KB
- mbrx20251121_8k_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the "Company") received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), which notified the Company that it did not comply with Nasdaq's Listing Rule 5550(b)(1) (the "Listing Rule"), which requires that the Company maintain a minimum of $2.5 million in stockholders' equity, and that the Company also did not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Staff had previously granted the Company an extension until November 19, 2025 to regain compliance with the Listing Rule. On November 20, 2025, the Company received a delist determination letter from the Staff (the "Nasdaq Notice") advising the Company that the Staff had determined that the Company had not regained compliance with the Listing Rule. Accordingly, the Staff indicated that unless the Company requests a hearing panel (a "Panel") appeal of the delist determination by November 28, 2025, its securities would be delisted on December 2, 2025. The Company intends to appeal Nasdaq's determination to a Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any suspension pending the Panel's determination and any further extension the Panel may grant. . Following the appeal request, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "MBRX". SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: November 21, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster Chief Financial Officer